Home > Press Releases > Lizza Named to the NJBIZ 2022 Law Power 50 List

Lizza Named to the NJBIZ 2022 Law Power 50 List

Published: 07/25/2022

Saul Ewing Arnstein & Lehr LLP is proud to announce that Charles M. Lizza, Vice Chair of the Firm’s Litigation Department and Co-Chair of its Intellectual Property Practice, was named to the NJBIZ 2022 Law Power 50 list. This is the fourth year in a row that Mr. Lizza has been included on this list of the state's top lawyers. Professionals are selected for the list based on their legal acumen and the results they have achieved for their clients in the state. 

Mr. Lizza currently serves as lead New Jersey litigation counsel in more than two dozen patent cases for approximately 20 major pharmaceutical companies. Examples of his work include representation of Helsinn Healthcare S.A. in major trial victories against Teva and Dr. Reddy’s involving the Aloxi brand drug product (market value of judgments $3.2 billion) and representing Janssen Pharmaceuticals, Inc. (“J&J”) and Mitsubishi Tanabe Pharma Corp. in a complete trial victory against Zydus involving the compound patent covering Janssen’s blockbuster Invokana diabetes drug product, with annual sales in the billions. Mr. Lizza also represents Celgene Corp. (BMS) in defending its Revlimid drug, a treatment for multiple myeloma and blood disorders, which produces annual sales in excess of $10 billion.

In public service, Mr. Lizza currently serves on the Board of Trustees of Saint Peter's University. He has served as Chairman of the Board of Directors of Covenant House New York and as Chairman of the Board of Trustees of Saint Peter's Prep in Jersey City, NJ.

Mr. Lizza's profile notes "…it’s no secret that the pharmaceutical industry plays a pivotal role in the state’s economy. Lizza helps those drugmakers protect some of their most valuable assets: intellectual property.”